Literature DB >> 22009384

National trends in surgical procedures for hepatocellular carcinoma: 1998-2008.

Hari Nathan1, Dorry L Segev, Skye C Mayo, Michael A Choti, Andrew M Cameron, Christopher L Wolfgang, Kenzo Hirose, Barish H Edil, Richard D Schulick, Timothy M Pawlik.   

Abstract

BACKGROUND: The incidence of hepatocellular carcinoma (HCC) is rising, and the options for surgical therapy of HCC have evolved recently, but use of surgical therapy has not been characterized on a representative, nationwide basis. We quantified trends in use, mortality, and patient and hospital characteristics for 3 surgical therapies for HCC (resection, ablation, and transplantation) in the United States from 1998 to 2008.
METHODS: Hospital discharge data from the Nationwide Inpatient Sample were used to quantify procedure-related data for each year. Trends over time were summarized as the average annual percent change (AAPC) and corresponding 95% confidence interval (CI).
RESULTS: The number of surgical procedures for HCC increased from 1416 to 6769 (AAPC, 13.5%; 95% CI, 10.2%-16.8%). Volumes increased for all surgical procedures, most notably for ablation (AAPC, 17.3%; 95% CI, 6.6%-29.2%) and transplantation (AAPC, 20.9%; 95% CI, 14.1%-28.1%). When analyzed as a proportion of total procedures, there were declines in the relative use of major hepatectomy (35% to 16%; AAPC, -7.2%, 95% CI, -8.8% to -5.6%) and wedge resection (37% to 22%; AAPC, -4.8%; 95% CI, -6.2% to -3.4%), while the proportion accounted for by transplantation increased (16% to 35%; AAPC, 4.4%; 95% CI, 0.2%-8.9%). Inpatient mortality decreased for each procedure individually and overall from 7.3% to 4.6% (AAPC, -7.7%; 95% CI, -10.8% to -4.5%), despite increasing age and comorbidity burden.
CONCLUSIONS: The use of surgical therapy for HCC has increased dramatically over the last decade, with a relative shift away from liver resection and toward liver transplantation. These therapeutic modalities must be better targeted to make the most appropriate use of limited health care resources.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Year:  2011        PMID: 22009384     DOI: 10.1002/cncr.26501

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma.

Authors:  Gaya Spolverato; Alessandro Vitale; Aslam Ejaz; Yuhree Kim; Shishir K Maithel; David P Cosgrove; Timothy M Pawlik
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

Review 2.  Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices.

Authors:  Nicole E Rich; Neehar D Parikh; Amit G Singal
Journal:  Curr Treat Options Gastroenterol       Date:  2017-06

Review 3.  Management of lymph nodes during resection of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a systematic review.

Authors:  Neda Amini; Aslam Ejaz; Gaya Spolverato; Shishir K Maithel; Yuhree Kim; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2014-10-10       Impact factor: 3.452

4.  Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis.

Authors:  Hari Nathan; Omar Hyder; Skye C Mayo; Kenzo Hirose; Christopher L Wolfgang; Michael A Choti; Timothy M Pawlik
Journal:  Ann Surg       Date:  2013-12       Impact factor: 12.969

5.  Is Hepatic Resection for Large or Multifocal Intrahepatic Cholangiocarcinoma Justified? Results from a Multi-Institutional Collaboration.

Authors:  Gaya Spolverato; Yuhree Kim; Sorin Alexandrescu; Irinel Popescu; Hugo P Marques; Luca Aldrighetti; T Clark Gamblin; John Miura; Shishir K Maithel; Malcolm H Squires; Carlo Pulitano; Charbel Sandroussi; Gilles Mentha; Todd W Bauer; Timothy Newhook; Feng Shen; George A Poultsides; J Wallis Marsh; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2014-10-30       Impact factor: 5.344

6.  A Novel Prediction Model for Bloodstream Infections in Hepatobiliary-Pancreatic Surgery Patients.

Authors:  Po-Sheng Yang; Chang-Pan Liu; Yi-Chiung Hsu; Chuen-Fei Chen; Chi-Chan Lee; Shih-Ping Cheng
Journal:  World J Surg       Date:  2019-05       Impact factor: 3.352

7.  A multicentre, randomized clinical trial comparing the Veriset™ haemostatic patch with fibrin sealant for the management of bleeding during hepatic surgery.

Authors:  Robert Öllinger; Andre L Mihaljevic; Christoph Schuhmacher; Hüseyin Bektas; Florian Vondran; Moritz Kleine; Mauricio Sainz-Barriga; Sascha Weiss; Phillip Knebel; Johann Pratschke; Roberto I Troisi
Journal:  HPB (Oxford)       Date:  2012-12-27       Impact factor: 3.647

8.  A risk model to predict 90-day mortality among patients undergoing hepatic resection.

Authors:  Omar Hyder; Carlo Pulitano; Amin Firoozmand; Rebecca Dodson; Christopher L Wolfgang; Michael A Choti; Luca Aldrighetti; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2013-03-09       Impact factor: 6.113

9.  Patient readmission and mortality after surgery for hepato-pancreato-biliary malignancies.

Authors:  Eric B Schneider; Omar Hyder; Christopher L Wolfgang; Kenzo Hirose; Michael A Choti; Martin A Makary; Joseph M Herman; John L Cameron; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2012-08-24       Impact factor: 6.113

10.  Trends in use of upper abdominal procedures in Sweden 1998-2011: a population-based study.

Authors:  Magnus Sundbom; Jakob Hedberg
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.